UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000003270 |
|---|---|
| Receipt number | R000003950 |
| Scientific Title | Multicenter Phase II study of erlotinib therapy in recurrent or advanced non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutation |
| Date of disclosure of the study information | 2010/03/01 |
| Last modified on | 2016/07/26 13:38:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Multicenter Phase II study of erlotinib therapy in recurrent or advanced non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutation
Acronym
Phase II Study of erlotinib in EGFR mutation Non-Small Cell Lung Cancer.
Scientific Title
Multicenter Phase II study of erlotinib therapy in recurrent or advanced non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutation
Scientific Title:Acronym
Phase II Study of erlotinib in EGFR mutation Non-Small Cell Lung Cancer.
Region
| Japan |
Condition
Condition
Non small cell lung cancer with Epidermal Growth Factor Receptor mutation
Classification by specialty
| Pneumology |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
To evaluate the efficacy and safety of erlotinib in advanced or recurrent NSCLC with EGFR mutation in Exon 19 and 21.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
Response Rate
Key secondary outcomes
Disease Contorol Rate,Safety,Progression Free Survival,Overall Survival
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Erlotinib treatment
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Histologically or cytologically proven stage IIIb or IV non-small cell lung cancer.
2) Patients who have previously treated one or two chemotherapy.
3) No previous treatment with EGFR-TKI
4) Patients having EGFR mutation (exon 19 deletion or L858R)
5)Possible cases with oral administration.
6) Patient who has at least one or more measurable lesion by RECIST.
7)Performance status (ECOG)0-2.
8) Patients who can be hospitalized for two weeks after beginning of the treatment or under management to apply to it.
9) Patients aged 20 years or older.
10) Sufficient function of main organ and bone marrow filled the following criteria before two weeks from enrollment:
*Leukocyte counts, 3,000/mm3 or over -12,000/mm3 or less.
*Neutrophil counts, 1,500/mm3 or over -5000/mm3 or less.
*Platelets, 100,000/mm3 or over.
*Hemoglobin, 9.0g/dL or over.
*AST and ALT, x 2 of upper limit of normal (ULN) or less.
*Serum bilirubin, 1.5mg/dl or less.
*Serum creatinin, x 1.5 of ULN or less.
*SpO2 90% or above(room air).
11) Patients who are considered to survive for more than 3 months.
12) Interval
(1)Chemotherapy: more than 4weeks after the last chemotherapy
(2)Radiation: more than 12weeks after the thoracic irradiation or more than 2weeks after the last irradiation to the other organs
(3)Operation: more than 4weeks after the last operation(including pleurodesis)
13)Written informed consent.
Key exclusion criteria
1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis.
2)Patients with massive pleural or pericardial effusion ,or ascites.
3)Patients with active severe infections.
4)Cases with past history of administration of HER related agents.
[ex) gefitinib, lapatinib, trsutuzumab, cetuximab]
5)Impossible cases with oral administration.
6)Patients with active opthalmological disease.
7) Patients with active concomitant malignancy.
8) Patients with symptomatic brain metastasis.
9)Patients with double cancer.
10)Patients with uncontrollabe diabetes mellitus.
11)Patients with uncontrollable complications.
12)Inappropriate patients for this study judged by the physicians.
Target sample size
26
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoichi Nakanishi |
Organization
Kyushu University, Graduate School of Medical Sciences
Division name
Research Institute for Diseases of the Chest
Zip code
Address
3-1-1 Maidashi, higashi-ku, Fukuoka, Japan , 812-8582
TEL
092-642-5378
yoichi@kokyu.med.kyushu-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Koichi Takayama |
Organization
Kyushu University, Graduate School of Medical Sciences
Division name
Research Institute for Diseases of the Chest
Zip code
Address
3-1-1 Maidashi, higashi-ku, Fukuoka, Japan , 812-8582
TEL
092-642-5378
Homepage URL
koichi-t@kokyu.med.kyushu-u.ac.jp
Sponsor or person
Institute
Lung Oncology Group in Kyushu, Japan (LOGIK)
Institute
Department
Personal name
Funding Source
Organization
Clinical Research Support Center Kyushu
Organization
Division
Category of Funding Organization
Non profit foundation
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
九州大学病院（福岡県）
浜の町病院（福岡県）
福岡大学（福岡県）
国立病院機構 福岡東医療センター（福岡県）
済生会福岡総合病院（福岡県）
国立病院機構 九州医療センター（福岡県）
公立学校共済組合 九州中央病院（福岡県）
国立病院機構 福岡病院 （福岡県）
飯塚病院（福岡県）
産業医科大学病院（福岡県）
国立病院機構 大牟田病院（福岡県）
九州厚生年金病院（福岡県）
福岡大学 筑紫病院（福岡県）
北九州市立医療センター（福岡県）
久留米大学（福岡県）
大分大学（大分県）
大分県立病院（大分県）
アルメイダ病院（大分県）
国立病院機構 大分医療センター（大分県）
佐賀大学（佐賀県）
長崎大学（長崎県）
健康保険諫早総合病院（長崎県）
春回会 井上病院（長崎県）
熊本大学
熊本地域医療センター（熊本県）
国立病院機構 熊本再春荘病院（熊本県）
熊本赤十字病院（熊本県）
国立病院機構 熊本医療センター（熊本県）
宮崎大学（宮崎県）
鹿児島大学（鹿児島県）
国立病院機構 南九州病院（鹿児島県）
川内医師会立市民病院（鹿児島県）
鹿児島厚生連病院（鹿児島県）
浦添総合病院（沖縄県）
琉球大学（沖縄県）
沖縄県立南部医療センター・こども医療センター（沖縄県）
国立病院機構 沖縄病院（沖縄県）
松山赤十字病院（愛媛県）
Other administrative information
Date of disclosure of the study information
| 2010 | Year | 03 | Month | 01 | Day |
Related information
URL releasing protocol
http://www.logik.jp/
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2009 | Year | 02 | Month | 20 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 05 | Month | 01 | Day |
Last follow-up date
| 2012 | Year | 01 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2010 | Year | 03 | Month | 01 | Day |
Last modified on
| 2016 | Year | 07 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003950
